MICHELLE STETTENBENZ: Open Payments
NPI 1346488012 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$433 in 21 payments from 13 companies in 2025. Trend: 2023 $132 · 2024 $206 · 2025 $433
Food & beverage: $433
| Company | Payments | Amount |
|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| UCB, Inc. | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| Alexion Pharmaceuticals, Inc. | 2 | $37 |
| SpringWorks Therapeutics, Inc. | 1 | $29 |
| TG Therapeutics, Inc. | 2 | $29 |
| GENZYME CORPORATION | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| ARGENX US, INC. | 1 | $16 |
Products named: FYCOMPA, HYQVIA, KESIMPTA, ULTOMIRIS, GOMEKLI, BRIUMVI, Nayzilam, Rystiggo.
Industry payments across KY — which companies pay providers there.
